Cytosorbents (CTSO) Q4 2024 earnings summary

Executive summary

• Achieved 25% Q4 product revenue growth year-over-year to $9.2M and 15% full-year growth to $35.6M, driven by international direct and distributor sales, with Germany sales flat.

• CytoSorb, the flagship product, saw over 270,000 devices used in 70+ countries, anchoring the core business.

• Regulatory milestones advanced for DrugSorb-ATR, with FDA De Novo and Health Canada applications under review and decisions expected in 2025; pre-launch and commercialization plans underway.

• Strengthened balance sheet through a $20M debt facility, $7.3M rights offering, warrant exercise, and improved cash management, increasing liquidity by $12.3M.

• Operational improvements and cost controls have moved the company closer to near cash flow breakeven, targeted for late 2025.

Financial highlights

• Q4 2024 product revenue: $9.2M (+25% YoY); full-year product revenue: $35.6M (+15% YoY); total revenue (historical convention): $10.2M in Q4 (+17%), $39.2M full year (+8%).

• Gross margin for Q4 and full year: 71%, up from 68% in Q4 2023.

• Q4 operating expenses down 30% YoY to $10.2M; Q4 operating loss improved 61% YoY to $3.7M; full-year operating loss improved 47% to $16.7M.

• Adjusted EBITDA loss for Q4 improved by 70% to $2.4M; full-year adjusted EBITDA loss improved by 56% to $11.5M.

• Adjusted net loss for 2024: $12.7M, or $0.23/share (improved from $27M, or $0.61/share, in 2023); net loss for 2024: $20.7M ($0.38/share).

Outlook and guidance

• Short-term disruption and modestly lower product sales in Q1 2025 expected due to German sales team reorganization; growth anticipated in the second half.

• Core business targeted to reach near break-even by end of 2025, exclusive of DrugSorb-ATR revenues.

• Regulatory decisions for DrugSorb-ATR expected in 2025, with preparations for controlled market release upon approval.